LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

Home・Lista de Ações・MannKind Corp

MannKind Corp

Abrir

SetorSaúde

3.18 -4.5

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.11

Máximo

3.34

Indicadores-chave
By Trading Economics
Rendimento	-24M -16M
Vendas	30M 112M
P/E Médio do Setor	140.5 49.8
EPS	0.01
Margem de lucro	-14.245
Funcionários	591
EBITDA	-20M -2.5M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+124.4% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-689M 868M
Abertura anterior	7.68
Fecho anterior	3.18

Sentimento de Notícias

By Acuity

81%

19%

326 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

4.079 / 4.323 Suporte e Resistência

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 22:50 UTC

Ganhos

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 de mai. de 2026, 22:49 UTC

Ganhos

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 de mai. de 2026, 22:32 UTC

Ganhos

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Ganhos

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 de mai. de 2026, 22:26 UTC

Ganhos

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure Interim Dividend A$0.50/Security

12 de mai. de 2026, 22:24 UTC

Ganhos

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 de mai. de 2026, 22:19 UTC

Ganhos

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 de mai. de 2026, 22:13 UTC

Ganhos

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 de mai. de 2026, 22:11 UTC

Ganhos

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 de mai. de 2026, 22:11 UTC

Ganhos

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 de mai. de 2026, 22:10 UTC

Ganhos

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 de mai. de 2026, 22:08 UTC

Ganhos

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 de mai. de 2026, 22:07 UTC

Ganhos

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 de mai. de 2026, 22:05 UTC

Ganhos

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

124.4% parte superior

Previsão para 12 meses

Média 7.54 USD 124.4%

Máximo 10 USD

Mínimo 4.75 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentimento

By Acuity

326 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.